Analysis of D-Dimer Level and Prothombin Time (PT) Activated Prothombin Thromboplastin (APTT) on Heparin Administration to COVID-19 Patients
Article Sidebar
Main Article Content
Abstract
Coronavirus Disease 2019 (COVID-19) is an infectious disease caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). Coronavirus is a dangerous pathogen that affects both humans and animals. Symptoms and indicators of COVID-19 infection include fever, cough, and shortness of breath, which are common in respiratory illnesses. COVID-19 has spread globally with high mortality and morbidity rates. Prothrombin Time (PT), Activated Prothrombin Thromboplastin (APTT), and D-Dimer parameters are blood tests to evaluate the coagulation status of COVID-19 patients, all these parameters increased in COVID-19 patients. This study aims at determininig the levels of D-Dimer, PT, and APTT in COVID-19 patients. Clinical and laboratory records were retrospectively reviewed from 100 cases of COVID-19 admitted to hospitals. This study used a a cross-sectional, descriptive, secondary data analysis design. The sample included patients from the Bhayangkara TK. I R.Said Sukanto Hospital between April-July 2021. The sample is a COVID-19 patient who was treated in the Intensive Care Unit (ICU), worsened, and given heparin. An independent variable is the administration of intravenous heparin at prophylactic doses. Dependent variables are D-Dimer, PT, and APTT values. The collected data is processed using Microsoft Office Excel and then being analyzed. D-Dimer, PT, and APTT levels in COVID-19 patients were initially high or increased after heparin administration decreased or became normal. In conclusion, there was a decrease in D-dimer levels, PT values, and APTT after administration of intravenous heparin at prophylactic doses.
Downloads
Article Details
Copyright (c) 2022 Dela Yorike, Muhammad Rizki Kurniawan, Mohamad Syafaat
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
References
Indranila KS, Imam BW, Widjaja. Diagnostic tests for examination of plasma D-Dimer levels in the diagnosis of ischemic stroke. [Uji diagnostik pemeriksaan kadar D-Dimer plasma pada diagnosis stroke iskemik], Fakultas Kedokteran Universitas Diponegoro Semarang; 2010.
Burhanuddin B, Mansyur A, Agus A, Misnah. Examination of Prothrombin Time and Activated Partial Thromboplastin Time with Humaclot VA and Sysmex CA 500. [Pemeriksaan Prothrombin Time dan Activated Partial Thromboplastin Time dengan Humaclot VA serta Sysmex CA 500]. Fakultas Kesehatan Masyarakat UNHAS; 2012.
M Fariz Al-Hakim. Comparison of hemostatic parameters in COVID-19 and Non-COVID-19 Patients. [Perbandingan parameter hemostatis pada pasien COVID-19 dan Non COVID-19]. Fakultas kedokteran Universitas Sriwijaya; 2020.
Maria KRK, Nur F, Halbina FH. COVID-19 diagnostic examination. [Pemeriksaan diagnostik COVID-19]. Jurnal Keperawatan Muhammadiyah; 2020.
Rizki A, Taofik R. Recent developments in anticoagulant therapy in COVID-19 patients with severe symptoms. [Perkembangan terkini terapi antikoagulan pada pasien COVID-19 dengan gejala berat]. Jurnal Sains, Farmasi, dan Klinis; 2020.
Mochamat, Taufik EN, Famila. Use of High-dose Heparin in COVID-19 Patients with ARDS and hypertension in the Intensive Care Unit (ICU). [Penggunaan heparin dosis tinggi pada pasien COVID-19 dengan ARDS dan hipertensi di Unit Perawatan Intensif (ICU)]. Jurnal Anestesiologi Indonesia. Fakultas Kedokteran Universitas Diponegoro; 2020.
Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020; 135(23), 2033-2040.
Rangga V, Soesilowati D. Comparison of subcutaneous and intravenous heparin on D-Dimer Levels in the prevention of Deep Vein Thrombosis. [Perbandingan pemberian heparin subkutan dan intravena terhadap kadar D-Dimer pada pencegahan Deep Vein Thrombosis]. Semarang: Universitas Diponegoro: 2012
Yao Y, Cao J, Wang Q, Shi Q, Liu K, Luo Z, Chen X, Chen S, Yu K, Huang Z, Hu B. D-dimer as a biomarker for disease severity and mortality in COVID-19 patients: a case control study. Journal of intensive care. 2020; 8 (1), 1-11.
Djoerban Z. Provision of Prophylactic Anticoagulants in Hospitalized Covid-19 patients. [Pemberian antikoagulan profilaksis pada pasien Covid-19 yang dirawat di Rumah Sakit]. Rekomendasi IDI. Jakarta, 2020.
Maharani C. Coronavirus Disease 2019/Covid-19. Program Karya Tugas Ilmiah Universitas Negri Jakarta; 2020.
Siska M, Aldo DP, Yelvi L. Corona Disease 2019 (Covid-19) pathogenesis, clinical manifestations, and treatment options. [Corona Disease 2019 (Covid-19) Patogenesis], manifestasi klinis, dan pilihan terapi. Jurnal Kedokteran dan Kesehatan. Fakultas Kedokteran Universitas Surabaya; 2021.
Misnah M. The Role of Prothrombin Time (PT) and Activated Partial Thromboplastin Time (APTT) parameters. [Peran parameter Prothombin Time (PT) dan Activated Partial Thromboplastin Time (APTT)]. Jurnal Klinik Patologi. 2020.
Sri T, Wahdaniah. The Role of Prothrombin Time (PT) and Activated Partial Thromboplastin Time (APTT) parameters. [Hubungan jumlah trombosit dengan Nilai Prothombin Time (PT) dan Activated Partial Thromboplastin Time (APTT) Pada Persiapan Tindakan Operasi Caesar]. Jurnal Laboratorium Khatulistiwa 1. 2017;(1),8-12.
Himawan S, Danu S, Sigit K. Comparison of subcutaneous and intravenous heparin in coagulation and D-Dimer studies in patients at risk for venous thrombosis. [Perbandingan pemberian heparin subkutan dan intravena terhadap studi koagulasi dan D-dimer pasien dengan risiko trombosis vena]. JAI (Jurnal Anestesiologi Indonesia). 2012; 4 (3), 164-170.
John WE, James CF, Jeffrey IW. A Test in Context: D-Dimer. Journal American College Of Cardiology. 2017; 70 (19), 2411-2420.
Ery L, Jati LP, Satrio AW. The Effect of deep vein thrombosis prophylaxis with subcutaneous and intravenous heparin on APTT and platelet count in critical patients in the ICU Dr. Kariadi Semarang. [Pengaruh profilaksis trombosis vena dalam dengan heparin subkutan dan intravena terhadap APTT dan jumlah trombosit pada pasien kritis di ICU RSUP Dr. Kariadi Semarang]. JAI (Jurnal Anestiologi Indonesia). 2012; 4 (3), 171-182.
Wael AM, Saad IM, Bassam A. Anticoagulation in COVID-19. Eur Heart J Cardiovasc Pharmacother. 2020; 6 (4), 260-261.
Gunawan ACV, Novita BD. Hyper-coagulation and the used of anticoagulant for patient with COVID-19. Jurnal Widya Medika, 2020; 6(2), 103-110.
Purba RT, Adhi MP, Kusumawardhani E, Hardian R, Tobing AL. Potential for giving Tocilizumab to COVID-19g in the ICU of Ulin Hospital Banjarmasin. [Potensi pemberian Tocilizumab pada pasien COVID-19 di ICU RSUD Ulin Banjarmasin]. JAI (Jurnal Anestesiologi Indonesia). 2020; 12(3), 17-33.
Adie SK, Farina N. Impact of COVID-19 on monitoring of therapeutic unfractionated heparin. Journal of Thrombosis and Thrombolysis. 2021; 51(3), 827-829.
Rusdiana T, Akbar R. Recent developments in anticoagulant therapy in severely symptomatic Covid-19 Patients. [Perkembangan terkini terapi antikoagulan pada pasien Covid-19 Bergejala Berat]. Jurnal Sains Farmasi & Klinis. 2020; 7(3), 244-250.
Willim HA, Hardigaloeh AT, Supit AI, Handriyani H. Coagulopathy in Coronavirus Disease-2019 (COVID-19). [Koagulopati pada Coronavirus Disease-2019 (COVID-19)]. Intisari Sains Medis. 2020; 11 (3): 749-756
Vlot EA, Van den Dool EJ, Hackeng CM, Sohne M, Noordzij PG, Van Dongen EPA. Anti Xa activity after high dose LMWH thrombosis prophylaxis in Covid-19 patients at the Intensive Care Unit. Thrombosis Research. 2020; 196, 1-3.
Van der Wal LI, Kroft LJM, Van Dam LF, Cobbaert CM, Eikenboom J, Huisman MV, de Jonge E. Early effects of unfractionated heparin on clinical and radiological signs and d-dimer levels in patients with COVID-19 associated pulmonary embolism: An observational cohort study. Thrombosis Research. 2021; 200, 130-132.
